Login to Your Account

Second try with warfarin alternative; Armetheon set to start phase III

By Nuala Moran
Staff Writer

Tuesday, September 8, 2015
LONDON - Armetheon Inc. is poised to open the pivotal phase III trial of its oral anticoagulant, tecarfarin, and is raising a private round to fund the 3,000-patient study, which has FDA special protocol assessment (SPA) status.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription